Taltz Market Report 2026

Taltz Market Overview

• The Taltz market growth in the historic period has been driven by increasing prevalence of psoriasis and psoriatic arthritis, availability of targeted biologic treatments • Market expansion is supported by increasing demand for personalized autoimmune treatments, rising investments in next-generation biologics • Growth Driver: Increasing Prevalence Of Autoimmune Diseases And The Role Of Targeted Therapies • Market Trend: Advancing Competitive Edge Through Regulatory Approvals • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Taltz Market?

Taltz (ixekizumab) is a prescription biologic medication, primarily used to treat autoimmune conditions such as moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammatory responses, helping to reduce symptoms like joint pain, skin lesions, and stiffness. The main indications of taltz include psoriasis, psoriatic arthritis, and ankylosing spondylitis. Psoriasis is a chronic skin condition where the immune system causes skin cells to grow too quickly, leading to patches of red, flaky, and inflamed skin. It is often found on the elbows, knees, and scalp. It can be administered as both a subcutaneous injection and an intravenous infusion and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is used by both pediatrics and adults.

What Is The Taltz Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized autoimmune treatments, rising investments in next-generation biologics, expansion of biologic use in early-stage disease, growing focus on patient-centric drug delivery, increasing innovation in inflammatory pathway targeting. Major trends in the forecast period include increasing use of il-17 inhibitors in autoimmune diseases, rising adoption of biologic therapies for chronic inflammation, expansion of self-injectable treatment options, growing focus on long-term disease control, enhanced patient monitoring and adherence programs.

What Are The Drivers Of The Taltz Market?

The rising prevalence of autoimmune diseases is expected to drive the taltz market going forward. Autoimmune diseases refer to conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues, leading to inflammation and damage. Autoimmune diseases are rising due to factors such as genetic predisposition, environmental triggers, lifestyle changes, and advancements in diagnostic techniques leading to better identification and awareness of these conditions. Taltz is used to treat autoimmune diseases, as it targets and inhibits specific inflammatory pathways, particularly interleukin-17A, to reduce inflammation and relieve symptoms associated with conditions such as psoriasis and psoriatic arthritis. For instance, in January 2025, according to the Mayo Clinic, a US-based nonprofit academic medical center, reports that about 15 million people are estimated to have one or more of 105 autoimmune diseases. Therefore, the growing prevalence of autoimmune disorders will drive the growth of the taltz industry. The increasing healthcare spending is expected to propel the growth of the taltz market going forward. Healthcare spending refers to the total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Increasing healthcare spending is driven by factors such as an aging population, the rise of chronic diseases, and higher demand for healthcare services. Increased healthcare spending positively impacts taltz by enabling greater access to advanced biologic therapies, improving diagnosis rates, and facilitating patient adherence through insurance coverage and support programs. For instance, in November 2025, according to Organisation for Economic Co-operation and Development, a US-based intergovernmental organization, reported that in 2024, OECD countries are estimated to have allocated around 9.3% of their GDP to health on average. Therefore, the increasing healthcare expenditure is driving the growth of the taltz industry.

Key Players In The Global Taltz Market

Major companies operating in the taltz market are Eli Lilly and Company

Global Taltz Market Trends and Insights

Major companies operating in the Taltz market are focusing on obtaining drug approvals to gain a competitive advantage and expand treatment options. Drug approval involves regulatory evaluation of a new drug’s safety, effectiveness, and quality based on clinical trial data. For instance, in July 2025, Eli Lilly and Company, a US-based pharmaceutical company, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending an update to the marketing authorization of Taltz (ixekizumab). This update would expand Taltz’s indication to include juvenile idiopathic arthritis (JIA), specifically juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), in children aged six years and older. While the active ingredient remains the same, this expansion addresses an unmet pediatric rheumatology need for patients with inadequate response or intolerance to conventional therapy, complementing Taltz’s existing adult indications.

What Defines the Taltz Market?

The taltz market consists of sales of injectables and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Taltz Market Report 2026?

The taltz market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the taltz industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.